Filing Details
- Accession Number:
- 0001181431-13-032856
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2013-06-05 16:01:48
- Reporting Period:
- 2013-06-05
- Filing Date:
- 2013-06-05
- Accepted Time:
- 2013-06-05 16:01:48
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1571498 | Epizyme Inc. | EPZM | Pharmaceutical Preparations (2834) | 261349956 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
318154 | Amgen Inc | One Amgen Center Drive Thousand Oaks CA 91320-1799 | No | No | Yes | No | |
1576997 | Amgen Ventures Llc | One Amgen Center Drive Thousand Oaks CA 91320-1799 | No | No | Yes | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock | Acquisiton | 2013-06-05 | 317,460 | $0.00 | 317,460 | No | 4 | C | Direct | |
Common Stock | Acquisiton | 2013-06-05 | 16,666 | $15.00 | 334,126 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | C | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Series B Preferred Stock | Disposition | 2013-06-05 | 952,381 | $0.00 | 317,460 | $0.00 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
0 | No | 4 | C | Direct |
Footnotes
- Each share of Series B Preferred Stock automatically converted into 1/3rd of a share of common stock upon the closing of the Issuer's initial public offering without payment of further consideration. The shares had no expiration date.
- These shares are owned directly by Amgen Ventures LLC, a wholly-owned subsidiary of Amgen Inc. (Amgen), and Amgen has the power to vote, acquire, hold and dispose of all shares. Amgen disclaims beneficial ownership of the securities except to the extent of its pecuniary interest therein.
- Upon the closing of the Issuer's initial public offering on June 5, 2013, the shares held by the reporting persons represent less than 10% beneficial ownership of the outstanding shares of common stock.